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Background: Pompe disease is an autosomal recessive lysosomal glycogen storage disorder that has been
reported in different ethnic populations which carry different common mutations of the acid alpha-glucosidase
(GAA) gene. The GAA mutation pattern in mainland Chinese patients with late-onset Pompe disease is still not well
understood.
Methods: We presented the clinical and genetic characteristics of 27 mainland Chinese late-onset Pompe patients
from 24 families.
Results: GAA mutation analysis revealed 26 different mutations, including 10 that were novel. The allelic frequency
of c.2238G > C (p.W746C) was found to be 27.08% in this patient group. Respiratory dysfunction was diagnosed in
10 of 11 patients who underwent pulmonary function evaluation, although only four required ventilator support at
night.
Conclusions: Our findings indicate that c.2238G > C (p.W746C) is the most common mutation in mainland Chinese
late-onset Pompe patients, as observed in Taiwanese patients. The novel mutations identified in this study expand
the genetic spectrum of late-onset Pompe disease, and the prevalence of respiratory dysfunction highlights the
importance of monitoring pulmonary function in late-onset Pompe patients.Background
Pompe disease (glycogen storage disease type II, acid
maltase deficiency, OMIM #232300) is an autosomal re-
cessive lysosomal glycogen storage disorder caused by a
deficiency of the lysosomal enzyme acid α-glucosidase
(GAA). Pompe disease occurs in approximately 1 per
40,000 births [1], and patients are typically classified as
early (infantile) or late-onset (childhood/juvenile/adult)
according to the age of symptom onset. Patients with
classical infantile-onset Pompe disease display a combin-
ation of generalized skeletal muscle weakness and car-
diac hypertrophy that provoke cardiorespiratory failure
and death within the first year of life [2]. Conversely, the* Correspondence: yuanyun2002@sohu.com
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unless otherwise stated.late-onset form of Pompe disease exhibits a less severe
phenotype with progressive proximal skeletal muscle
weakness and respiratory muscle involvement. These
nonspecific symptoms often make Pompe disease clinic-
ally difficult to differentiate from other neuromuscular
diseases, but valuable evidence can be provided by meas-
urement of decreased GAA activity, observations of vac-
uoles in muscle fibers on muscle biopsy, and genetic
tests of the GAA gene [3,4].
This gene has been mapped to chromosome 17q25.2–
q25.3; it contains 20 exons and the first amino acid is
encoded by exon 2. Pathogenic sequence variations in
GAA can lead to complete or partial loss of lysosomal
GAA activity, and a close correlation exists between the
functional GAA protein and clinical phenotype: the less
residual GAA activity, the earlier the onset and greater
the severity of the disease [5,6]. To date, over 400 differ-
ent mutations have been described [see http://www.s is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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siderable frequency in distinct ethnic groups. For ex-
ample, c.-32-13 T > G is the most common mutation in
Caucasian patients with a frequency as high as 34–47%
[4,7-11]. Conversely, c.1935C >A (p.D645E) and c.2238G >
C (p.W746C) are common in Taiwanese patients [12].
Awareness of Pompe disease has been increasing in
recent years, and more cases have been reported world-
wide [13-15]. However, limited data have been pub-
lished about mainland Chinese late-onset Pompe
patients [16-18]. We herein present the clinical features
and GAA mutation pattern of 27 patients from 24 un-




Twenty-seven patients from 24 unrelated families (Table 1)
who were diagnosed with Pompe disease at the De-
partment of Neurology, Peking University First Hospital
(Peking, China) from 2003 to 2013, were recruited in this
study. None of the patients had consanguineous parents.
Their confirmatory diagnosis was based on clinical fea-
tures, biochemical assay, muscle pathology, and molecular
tests. All patients gave their informed consent for this
study, and ethical approval for the study was obtained
from the health authority ethical committee of Peking
University First Hospital.
Clinical data included disease history and physical exa-
mination. Eleven patients with the late-onset form of
Pompe disease underwent a respiratory function evalu-
ation, including measurement of forced vital capacity
(FVC) in a sitting and supine position, forced expiratory
volume in one second (FEV1), maximal inspiratory pres-
sure (MIP), maximal expiratory pressure (MEP), and
cough peak flow (CPF).
Muscle pathology
Muscle biopsies were carried out in 19 patients. Muscle
specimens were snap frozen in cooled isopentane, and then
stored at −80°C until required for analysis. Cryostat sections
were prepared and stained according to standard proce-
dures with hematoxylin eosin, modified Gomori trichrome,
periodic acid-Schiff (PAS), oil red O, adenosine triphospha-
tase, nicotinamide adenine dinucleotide-tetrazolium reduc-
tase (NADH-TR), succinate dehydrogenase, cytochrome c
oxidase (COX), and non-specific esterase.
Biochemical assays
In 15 of the 27 patients, GAA enzyme activity in dried blood
spots (DBS) was determined with 4- methylumbelliferyl-
alpha-D-glucoside (4-MUG) as the substrate and acarbose
as an inhibitor of maltose glucoamylase (MGA) using a
fluorometric assay as described [19].GAA mutation analysis
GAA mutation screening was performed in all patients.
Genomic DNA was extracted from peripheral blood or
frozen muscle biopsy specimens using standard proce-
dures. All GAA exons and intron/exon boundaries were
amplified by PCR, and then PCR products were purified
and sequenced using an ABI 3730XL automatic sequen-
cing machine (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA). Sequences were compared with the
GAA reference DNA sequence (GenBank Accession:
NM_000152) to identify pathogenic mutations. The cDNA
was numbered with +1 corresponding to the A of the
ATG translation initiation codon and with codon 1 as the
initiation codon. The pathogenic nature of novel missense
mutations was verified by direct sequencing of 100 unre-
lated healthy individuals. Additionally, GAA mutation
analysis was performed in the parents of seven Pompe pa-
tients after obtaining their informed consent. To deter-
mine the effect of a possible splice-site mutation (c.1551 +
3_c.1551 + 6delAAGT) in intron 9, we extracted Total
RNA from Patient 20′s muscle samples, and amplified the
whole cDNA by reverse transcriptase-polymerase chain
reaction (RT-PCR) using the SuperScript III First-Strand
DNA Synthesis kit (Invitrogen, Carlsbad, CA, USA). A
region encompassing exons 9–10 was amplified using
primers G9-10 F: 5′- CGTTCAACAAGGATGGCTTC-3′
and G9-10R: 5′-GTGGGTTCTCCAGCTCATTG-3′. PCR
products were analyzed by agarose electrophoresis.
Results
Clinical manifestations of patients
The clinical features of the 27 patients (9 male, 18 female)
are summarized in Table 1. Patients 23 and 24 are a sibling
pair, and patients 25, 26, and 27 are also siblings.
In present study, the patients’ age at onset ranged from
1.2–32 years with a median age of 21 years. Twenty-one
(77.8%) complained of muscle weakness as their initial and
main symptom. All patients had skeletal muscle weakness
predominantly affecting the proximal extremities. Four pa-
tients reported that respiratory insufficiency was the initial
clinical symptom that prompted them to seek medical
help. Two patients presented with hyperCKemia as their
initial symptoms. The median age at diagnosis was 22 years
(range, 3–35 years). Eighteen patients had their diagnosis
confirmed initially by muscle pathology, followed by muta-
tion detection and/or GAA activity assay. Six patients were
diagnosed by a combination of GAA activity assay and
genetic analysis, and three patients by genetic analysis
alone.
With disease progression, 15 late-onset patients suffered
respiratory dysfunction, and persistent or intermittent
assisted respiration was required in 10 of these (Table 1).
The median serum creatine kinase (CK) level was 700 IU/
L (range, 79.0–2,391.6 IU/L). The echocardiography





















1 F/3 1.2 3 Muscle weakness No 568 Vacuolar
myopathy
ND c.503G > A c.2237G > A Yes




ND c.503G > C c.1082C > T No
3 M/14 8 14 Muscle weakness No 907 Vacuolar
myopathy
ND c.796C > T c.1309C > T No
4 F/22 5 22 Muscle weakness No 1101 Vacuolar
myopathy
ND c.1562A > T c.1781G > A No
5 M/30 10 30 Muscle weakness No 642 Vacuolar
myopathy
ND c.503G > A c.2237G > A No
6 F/23 21 21 Limb girdle weakness No 1047 ND 0 c.1355delC c.2238G > C Yes
7 M/17 17 17 Muscle weakness No 1413 ND ND c.2238G > C c.2238G > C No
8 M/12 12 12 Muscle weakness No 1365 Vacuolar
myopathy
3.15 c.871C > T c.2238G > C No
9 M/23 21 21 Limb girdle weakness No 2391.6 ND 2.25 c.323G > A c.2014C > T No
10 M/14 6 13 Respiratory insufficiency No 637 Vacuolar
myopathy
3.96 c.1935C > A c.2238G > C No
11 F/17 3 4 High level of serum CK No 1227 Vacuolar
myopathy
0.25 c.2238G > C c.2662G > T No
12 F/15 10 13 Limb girdle weakness No ND Vacuolar
Myopathy
4.04 c.2238G > C No
13 F/24 12 20 Muscle weakness No 1200 Vacuolar
myopathy
1.15 c.1561G > A c.2161G > T Yes
14 F/25 15 23 Muscle weakness No 662.6 Vacuolar
myopathy
ND c.1315_1317delATG c.2238G > C Yes
15 F/35 29 35 Muscle weakness No 406 Vacuolar
myopathy
3.54 c.1082C > T No
16 F/33 32 32 High level of serum CK No 927 Vacuolar
myopathy
3.32 c.-32-13 T > G c.2662G > T No




8.05 c.1634C > T c.2662G > T No
18 F/35 25 25 Sleep disordered breathing No 79 Vacuolar
myopathy
ND c.2238G > C c.2431delC Yes
19 M/20 19 20 Limb girdle weakness No 800 Vacuolar
myopathy
3.46 c.1634C > T c.1993G > A Yes
20 F/23 23 23 Respiratory insufficiency No 345 Vacuolar
myopathy
5.98 c.1551 + 3_c.1551 +
6delAAGT













Table 1 Clinical, enzymatic, and molecular information of 27 Chinese patients with late-onset Pompe disease (Continued)
21 F/32 23 30 Muscle weakness No 139 Vacuolar
myopathy
1.1 c.1935C > A c.2238G > C Yes
22 F/14 9 14 Limb girdle weakness No 970 Vacuolar
myopathy
ND c.2446G > A c.2662G > T No
232 F/30 24 30 Muscle weakness Yes 563 ND ND c.1396delG c.2238G > C No
242 F/28 23 28 Muscle weakness Yes 746 ND ND c.1396delG c.2238G > C No
253 M/24 16 22 respiratory insufficiency and fatigue Yes 790 ND 0 c.241C > T c.2238G > C Yes
263 F/31 12 28 Muscle weakness Yes ND ND 0.6 c.241C > T c.2238G > C No
273 F/29 27 27 Limb girdle and muscle weakness Yes 303 ND 0.44 c.241C > T c.2238G > C Yes
1 The median activities of 19 normal controls and 14 carriers were 36.37(range, 15.16–297.86) and 24.77 (range, 11.84–43.97) pmol/punch/hour, respectively.













Figure 1 Myopathological changes in Patient 2 (A and B), Patient 12 (C and D) and Patient 22 (E and F). H&E staining shows extensive
vacuolation in many fibers in Patient 2 (A), but only a few vacuolar fibers in Patient 12 (C) and Patient 22 (E). Vacuolar fibers stained positive for
glycogen with PAS (B, D and F).
Figure 2 GAA mutation spectrums in 27 Chinese late-onset Pompe patients. All described mutations are shown above (blue, UTR; purple,
introns; orange, exons).
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Figure 3 Exon 10 skipping in Patient 20. Muscle cDNA was
amplified with the primers encompassing exon 9 and 10 that
normally yield a 381-bp fragment. An additional 267-bp fragment
was detected in Patient 20. The 114-bp difference is exactly the
same with the size of exon 10.
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cant abnormality. Respiratory function evaluation in 11
late-onset patients (four requiring respiratory assistance at
night) revealed that 90.90% (10/11) were abnormal. Fur-
ther detailed clinical information has been reported by us
previously [17].
Muscle pathology
All 19 patients who underwent muscle biopsy showed
muscle fibers with vacuoles that stained positive for
glycogen in a PAS stain. The proportion of vacuolar fi-
bers was various among all the patients (Figure 1).
GAA activity assay
The median GAA activity of 16 patients was 2.70 pmol/
punch/hour (range, 0–8.05), while the median activities
of 19 normal controls and 14 carriers were 36.37(range,
15.16–297.86) and 24.77 (range, 11.84–43.97) pmol/punch/
hour, respectively.
GAA mutations
Among the 27 patients recruited in this study there were
five sibling pairs from two separate families, so 24 unrelated
families are presented. GAA mutation analysis disclosed 21
families with compound heterozygous mutations, one with
homozygous mutations, and two with only one heterozy-
gous mutation (Table 1). A total of 26 different mutations
were detected in the 24 families (Table 1, Figure 2), includ-
ing 18 missense mutations, two nonsense mutations, four
deletion mutations, and two splice site mutations. Fifteen
patients from 12 families carried the c.2238G >C mutation,
including 14 compound heterozygotes and one homo-
zygote. The allele frequency of the c.2238G >C mutation
in our patients was therefore 27.08% (13/48). Of the 26 mu-
tations, 15 (c.503G >A, c.796C >T, c.871C >T, c.1082C >
T, c.1309C > T, c.1561G > A, c.1634C > T, c.1781G >
A, c.1935C > A, c.2014C > T, c.2238G > C, c.2662G > T,
c.2237G >A, c.1396delG, and c.-32-13 T >G) have previ-
ously been reported as pathogenic, one (c.2446G >A) was
reported as non-pathogenic[see http://www.pompecenter.
nl], but the other 10 (c.323G > A, c.503G > C, c.1562A > T,
c.1993G >A, c.241C > T, c.2161G > T, c.1355delC, c.1315_
1317delATG, c.2431delC, and c.1551 + 3_c.1551 + 6del
AAGT) are novel.
None of the 10 novel mutations were detected in 100
unrelated healthy controls. The c.241C > T and c.2161G >
T mutations lead to a premature stop in protein synthesis,
which was assumed to be deleterious since stop codons lo-
cated upstream of the main stop codon could result in
truncated protein. There were four novel small deletions
detected, among them c.1551 + 3_c.1551 + 6delAAGTcon-
firmed to cause exon 10 skipping by RT-PCR (Figure 3),
c.1355delC, and c.2431delC mutations predicted to cause
a frame shift effect, while c.1315_1317delATG predicted tocause in frame deletion. Of the four novel missense muta-
tions, the amino acids mutated in p.Glu521Val (c.1562A >
T) and p.Gly665Arg (c.1993G >A) are highly conserved
across the examined species (Figure 4), suggesting that
they are potentially pathogenic. p.Cys108Tyr (c.323G >A)
Figure 4 Conservation of four novel missense mutations in different species.
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served, indicating that the mutations are more likely to
be mild in severity. The healthy parents of patients 11
(c.323G > A; c.2014C > T) and 21 (c.1634C > T; c.1993G >
A) were found to carry one heterozygous mutation each
that were present in their offspring.
Discussion
Although Pompe disease is rare, it has been reported in a
number of different ethnic populations, such as Caucasian,
Taiwanese, Korean and Japanese [4,7-12,20-23]. This study
is the largest series of mainland Chinese late-onset Pompe
patients, including 27 patients from 24 unrelated families.
Our results showed that the majority of our patients (15/
27, 55.56%) carried the c.2238G >C mutation of GAA,
and that the allele frequency of c.2238G >C was as high as
27.08%, making it the most common mutation in this
group. This result is consistent with findings in Taiwanese
Pompe patients [12], but different from the common mu-
tation (c.1935C >A) in mainland Chinese infantile-onset
group [24].Meanwhile, c.-32-13 T >G, the most common
mutation of Caucasian origin with a frequency of 34–79%
[3,4,7-10], was found in only one patient with compound
heterozygous mutations in the present study. Other com-
mon mutations reported in certain populations, such as
c.1316 T >A and c.1857C >G with a frequency of 36.6%
in Korean patients [20], c.1064 T > C which is the predom-
inant mutation in Portuguese patients [21], c.1726G >A
with a frequency of up to 27.59% in Japanese patients [22],
and the African-American mutation c.2560 C > T [23],
were not detected in our patients. Our study therefore fur-
ther supports the findings that different populations have
different mutation hotspots.
As c.1935C > A, the other common mutation in Taiwan,
was detected in only one patient from our group, and add-
itionally, c.1726 G > A and c.2065G > A pseudodeficiency
mutations which are common in Taiwanese, were absent
in the present study, this suggests that the spectrum of
GAA mutation differs not only between ethnicities but
also from region to region in the same population. Theabsence of c.[2238G >C; 1726G >A] haplotype in our pa-
tients raises the possibility that the c.2238G >C mutation
might have a different ancestor in Taiwan and mainland
China. Further research involving more patients is needed
to confirm this.
The diagnosis of this patients group with late-onset
Pompe disease depended on the combination of clinical
manifestations, muscle biopsy, blood-based GAA activity
assay and GAA gene analysis. The mean age of onset the
patients in the current study was 17.41 ± 8.99 years, which
is younger than a previous investigation of a Caucasian
background, and is in keeping with the study in Taiwanese
Pompe patients [3,10]. The difference in onset age between
Chinese and Caucasian patients with Pompe disease may
be caused by the prevalence of the c.2238 G >C mutation
and the low frequency of c.-32-13 T >G in the present set
of patients, as different mutations have different effects on
enzyme activity [12]. Muscular weakness was the most
common initial symptom in our study, as seen in an earlier
work; [25] however, it is noteworthy that respiratory im-
pairment was very common in our late-onset patients,
which is in contrast to the study in Germany in which no
patients had respiratory symptoms [25].
Dyspnea without limb weakness was the first reported
symptom in four of the current patients, while 10/27
(37.0%) of late-onset patients needed mechanical ventila-
tion within 2.5 years of disease onset. Moreover, in the
seven patients without mechanical ventilation, pulmonary
function evaluation revealed decreased pulmonary func-
tion in six. Together, our data support previous findings
that monitoring pulmonary function is essential in late-
onset Pompe disease to evaluate the need for mechanical
ventilation [1,26,27].
Notably, in 18 of 27 late-onset patients, diagnosis of
Pompe disease was confirmed initially by muscle pathology.
Although a blood-based assay has been widely recom-
mended as a simple diagnostic method, we still consider
muscle biopsy to be a very useful tool as the diagnosis of
Pompe disease can be challenging because of its heteroge-
neous clinical presentation and considerable overlap of
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eases [28,29]. This is particular important in east Asia,
where the high frequency of the p.[G576S;E689K] pseudo-
deficiency mutation in these ethnic populations can give
false positive results of GAA activity. Moreover, it is not
uncommon that only one pathogenic heterozygous muta-
tion is detected in coding region of GAA gene in Pompe
patients, as in patient 12, 15, and 22 of this group. In such
cases, muscle pathology can provide solid evidence for dis-
ease diagnosis (Figure 1, Table 1). However, it should men-
tioned that the muscle biopsy still has its limitation in
diagnosing Pompe disease due to the heterogeneity of
muscle involvement, especially in patients with late onset
Pompe disease [30].
Conclusions
Our findings indicate that c.2238G > C (p.W746C) is the
most common mutation in mainland Chinese late-onset
Pompe patients, as observed in Taiwanese patients. The
novel mutations identified in this study expand the gen-
etic spectrum of late-onset Pompe disease, and the
prevalence of respiratory dysfunction highlights the im-
portance of monitoring pulmonary function in late-onset
Pompe patients.
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